ProPublica
ProPublica is an independent, nonprofit newsroom that produces investigative journalism with moral force. Learn more.
Double Dose: In Second Case of Flawed Drug Research, FDA Response Was Slow and Secretive
This week ProPublica reported that the Food and Drug Administration found "egregious" research violations at a major laboratory but didn't pull any affected drugs from the market and, years later, hasn't finished its review. Turns out that wasn't an anomaly.
Five Drugs the FDA Doesn't Want You to Know Relied on Tainted Data
ProPublica was able to pinpoint five drugs whose approval rested, at least in part, upon data from a now defunct firm with "egregious" research violations
FDA Let Drugs Approved on Fraudulent Research Stay on the Market
In 2010, the FDA uncovered violations it later called "egregious" and "pervasive" at a major pharmaceutical testing lab. But even though the agency no longer knew for sure that drugs tested at the lab were safe, it allowed them to remain on pharmacy shelves with no new testing — in some cases until now. And the FDA won’t name the drugs.
No Substitute: When a Generic Drug Isn't What it Seems
Generic medications are generally safe and effective, because the Food and Drug Administration requests tests to prove they're equivalent to the name-brand originals. But here's a case where something went wrong.
A MuckReads Guide to North Korea
As tensions simmer over North Korea’s latest nuclear threats, we take a look at some of the best reading on Kim Jong Un, the prospects for a nuclear conflict and life in the DPRK.
From Citizens United to Super PACs: A Campaign Finance Reading Guide
On Tuesday, the Supreme Court agreed to hear a case challenging caps on overall campaign contributions. We roundup the most important stories on campaign finance, and the dark money groups that don’t have to report their donors.
Lawmakers Press for Answers on Sale of Wild Horses
Two congressmen have asked the U.S. Department of Interior for information on the progress of its investigation into the sale of more than 1,700 protected mustangs to a proponent of horse slaughter.